Capital Investment Advisors’s ARK Genomic Revolution ETF ARKG Stock Holding History

Capital Investment Advisors’s Portfolio ARKG Stock Details ARKG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-6,565	Closed	-$216K	–	582
2022 Q3	$216K	Sell	6,565 -2,272	-26%	-$83.4K	0.01%	483
2022 Q2	$278K	Buy	8,837 +411	+5%	+$14.4K	0.01%	452
2022 Q1	$387K	Buy	8,426 +117	+1%	+$5.58K	0.01%	408
2021 Q4	$509K	Sell	8,309 -2,090	-20%	-$144K	0.02%	368
2021 Q3	$777K	Sell	10,399 -23	-0.2%	-$1.93K	0.03%	306
2021 Q2	$964K	Sell	10,422 -6,294	-38%	-$535K	0.03%	275
2021 Q1	$1.48M	Buy	16,716 +2,504	+18%	+$248K	0.06%	204
2020 Q4	$1.32M	Buy	14,212 +7,412	+109%	+$591K	0.06%	199
2020 Q3	$433K	Buy	+6,800	New	+$398K	0.02%	335

Other funds holding ARKG

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

State of Wisconsin Investment Board Madison, Wisconsin $49.6B AUM 39.59% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Capital Investment Advisors's ARKG Position: Q4 2022 in Review

Capital Investment Advisors sold out of ARK Genomic Revolution ETF (ARKG) in Q4 2022, closing a stake of 6,565 shares — an estimated $216K sold.

Capital Investment Advisors first reported a position in ARKG in Q3 2020 and held it in 9 quarters. The position peaked at $1.48M in Q1 2021. 321 funds tracked by Wall St. Rank hold ARKG as of Q4 2022.

Capital Investment Advisors reported no remaining ARK Genomic Revolution ETF position as of Q4 2022 after selling out during the quarter.
Capital Investment Advisors sold 6,565 ARK Genomic Revolution ETF shares in Q4 2022, an estimated $216K.
Capital Investment Advisors first reported a position in ARK Genomic Revolution ETF in Q3 2020 and held it in 9 quarters.
Capital Investment Advisors's ARK Genomic Revolution ETF position peaked at $1.48M in Q1 2021.
321 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q4 2022.

Based on Capital Investment Advisors's 13F filing for Q4 2022, filed 5 Jan 2023.